
Stayble Therapeutics Investor Relations Material
Latest events

CEO Sitdown with Kalqyl Q4 2023
Stayble Therapeutics

Q2 2025
20 Aug, 2025

Q1 2025
21 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Stayble Therapeutics
Access all reports
Stayble Therapeutics is a clinical-stage biotechnology company developing non-surgical treatments for chronic disc-related back pain. Its lead candidate targets degenerative disc disease using injectable therapeutics. The company is headquartered in Gothenburg, Sweden, and its shares are listed on the Nasdaq First North Growth Market.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
STABL
Country
🇸🇪 Sweden